

PRESS RELEASE

For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED

Representative: Takashi Shoda, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)

Please address inquiries to Toshio Takahashi, Corporate Officer in Charge,
Corporate Communications Department

Telephone: +81-3-6225-1126


<http://www.daiichisankyo.com/>

—
DAIICHI SANKYO EUROPE is applying for approval of its new combination product of
Olmesartan and Amlodipin Approval requested in 28 European countries

The attached is the press release of Daiichi Sankyo Europe GmbH ;Europe affiliate of
DAIICHI SANKYO COMPANY LIMITED.

—

—



New product under development for the treatment of high blood pressure

DAIICHI SANKYO EUROPE is applying for approval of its new combination product of Olmesartan and Amlodipin

Approval requested in 28 European countries

Munich, October 1st 2007 – DAIICHI SANKYO EUROPE GmbH has applied in 28 European countries for approval of a new antihypertensive medication. It is a fixed combination (CS-8663) of two substances, the angiotensin receptor blocker (ARB) Olmesartan and the calcium antagonist Amlodipin.

When approved, the new combination for treatment of essential hypertension is designed for use in patients whose blood pressure cannot be adequately controlled through therapy with the respective monopreparation. In clinical trials the combination of Olmesartan / Amlodipin (CS-8663) has shown a significant lowering of blood pressure. In the new fixed combination, two complementary therapeutic approaches are combined: blocking of the angiotensin II receptor and blocking of the calcium channel. Olmesartan is already being marketed by DAIICHI SANKYO and is the angiotensin receptor blocker with the greatest sales growth in Europe¹. Amlodipin is one of the most frequently used calcium antagonists in many European countries.

“Hypertension is currently viewed as the number one cause of death. Most patients need two or even more medications to normalise their blood pressure.

The new fixed combination has proved to be effective and well tolerated in a large number of patients. That also applies to patients who have very high blood pressure at the start of therapy,” says Dr Petra Laeis, Head of Clinical Research at DAIICHI SANKYO EUROPE. “The combination of the two well-known agents Olmesartan and Amlodipin in one tablet gives doctors another effective treatment option for hypertension, which can lead to better results because patients are more likely to use it faithfully,” continues Dr Laeis.

DAIICHI SANKYO is a worldwide, research-oriented pharmaceutical company, created through the merger of the two traditional Japanese enterprises Daiichi and Sankyo. The company is one of the world’s leading manufacturers of medication. The company’s research activities focus on the areas of cardiovascular, haematology, diabetes, anti-infectives and cancer. DAIICHI SANKYO has its European headquarters in Munich.

For additional information, please visit our website at

<http://www.daiichi-sankyo.eu/>

¹ Source: IMS MIDAS Juli 2007

CONTACT

Dr Andrea Jäger ·

Vice Director Operative Marketing ·

Telephone +49(0)89/78 08-454 ·

andrea.jaeger@daiichi-sankyo.eu